INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK
Pomerantz Law Firm is investigating a class action lawsuit against Cytokinetics (CYTK) regarding potential securities fraud.Summary
Pomerantz LLP has announced a class action lawsuit against Cytokinetics, Incorporate (NASDAQ: CYTK) and is urging investors who experienced losses to contact them. The lawsuit alleges potential securities fraud related to the company’s New Drug Application (NDA) for aficamten. Specifically, the FDA initially decided against an advisory committee review, then extended the review date due to a Risk Evaluation and Mitigation Strategy (REMS) that wasn’t initially included in the NDA submission. Following these disclosures, Cytokinetics’ stock price experienced significant declines on May 1st and May 6th, 2025. Investors who purchased Cytokinetics securities during the class period have until November 17, 2025, to seek appointment as Lead Plaintiff. Pomerantz LLP, a leading firm in corporate and securities litigation, is handling the case and can be contacted at [email protected] or 646-581-9980.
(Source：FinancialContent)